Bhuyan Rupak, Maggio Tyler, Thomas Christie, Sambharia Meenakshi, Gehrs Karen, Boyce Timothy
Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Department of Internal Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Am J Ophthalmol Case Rep. 2024 Aug 22;36:102156. doi: 10.1016/j.ajoc.2024.102156. eCollection 2024 Dec.
To report a previously undescribed case of late-onset vision loss due to retinal oxalosis in a patient with primary hyperoxaluria type 2 (PH2).
An 82-year-old female with a history of biopsy-proven oxalate nephropathy developed vision loss 8 months after end stage kidney disease. She developed progressive retinal ischemia secondary to crystal deposition. She was presumed to have retinal oxalosis, and genetic testing confirmed PH2. Her retinopathy occurred once renal clearance fellow below hepatic oxalate production. The only effective treatment is kidney transplantation, but this patient was not a candidate.
To date, this is the most delayed-onset and severe reported case of progressive ischemic retinopathy from PH2. Patients with systemic oxalosis should be referred for genetic testing, as there are new RNA interference treatments approved for other subtypes of primary hyperoxaluria.
报告1例2型原发性高草酸尿症(PH2)患者因视网膜草酸沉着症导致迟发性视力丧失的此前未描述的病例。
一名82岁女性,有经活检证实的草酸肾病病史,在终末期肾病8个月后出现视力丧失。她因晶体沉积继发进行性视网膜缺血。推测她患有视网膜草酸沉着症,基因检测证实为PH2。她的视网膜病变发生在肾脏清除率低于肝脏草酸生成量之时。唯一有效的治疗方法是肾移植,但该患者不适合。
迄今为止,这是报道的PH2所致进行性缺血性视网膜病变中发病最延迟且最严重的病例。系统性草酸沉着症患者应转诊进行基因检测,因为有新的RNA干扰疗法已被批准用于原发性高草酸尿症的其他亚型。